Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia

A Hartman; R H N van Schaik; I P van der Heiden; M J C Broekhuis; M Meier; M L den Boer; R Pieters

doi:10.1016/j.leukres.2009.04.027

Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia

A Hartman, R H N van Schaik, I P van der Heiden, M J C Broekhuis, M Meier, M L den Boer, R Pieters

Onderzoeksoutput: Bijdrage aan tijdschrift › Artikel › peer review

30 Citaten (Scopus)

Samenvatting

INTRODUCTION: Impaired motor performance in children who completed treatment for acute lymphoblastic leukemia (ALL) may be related to polymorphisms of the metabolising gene CYP3A5 or vincristine toxicity related genes MDR-1 and MAPT.

METHODS: Motor performance was measured with the Movement Assessment Battery for Children (movement-ABC). DNA, from mononuclear blood cells was genotyped for CYP3A5, MDR-1 and MAPT polymorphisms.

RESULTS: Motor performance was not significantly affected by CYP3A5*3/*3 and CYP3A5*1*3 genotypes, MDR-1 polymorphisms or MAPT haplotype.

CONCLUSION: Our data did not show that CYP3A5, MDR-1 or MAPT polymorphisms are linked to impaired motor performance in children after treatment for ALL.

Originele taal-2	Engels
Pagina's (van-tot)	154-9
Aantal pagina's	6
Tijdschrift	Leukemia research
Volume	34
Nummer van het tijdschrift	2
DOI's	https://doi.org/10.1016/j.leukres.2009.04.027
Status	Gepubliceerd - feb. 2010
Extern gepubliceerd	Ja

Toegang tot document

10.1016/j.leukres.2009.04.027

Citeer dit

@article{042bb54ff22248078830a77cc3512c8b,

title = "Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia",

abstract = "INTRODUCTION: Impaired motor performance in children who completed treatment for acute lymphoblastic leukemia (ALL) may be related to polymorphisms of the metabolising gene CYP3A5 or vincristine toxicity related genes MDR-1 and MAPT.METHODS: Motor performance was measured with the Movement Assessment Battery for Children (movement-ABC). DNA, from mononuclear blood cells was genotyped for CYP3A5, MDR-1 and MAPT polymorphisms.RESULTS: Motor performance was not significantly affected by CYP3A5*3/*3 and CYP3A5*1*3 genotypes, MDR-1 polymorphisms or MAPT haplotype.CONCLUSION: Our data did not show that CYP3A5, MDR-1 or MAPT polymorphisms are linked to impaired motor performance in children after treatment for ALL.",

keywords = "ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics, Child, Child, Preschool, Cytochrome P-450 CYP3A/genetics, Drug Resistance, Neoplasm/genetics, Female, Genotype, Humans, Male, Pharmacogenetics, Polymorphism, Genetic, Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications, Psychomotor Performance/drug effects, Vincristine/pharmacokinetics, tau Proteins/genetics",

author = "A Hartman and \{van Schaik\}, \{R H N\} and \{van der Heiden\}, \{I P\} and Broekhuis, \{M J C\} and M Meier and \{den Boer\}, \{M L\} and R Pieters",

year = "2010",

month = feb,

doi = "10.1016/j.leukres.2009.04.027",

language = "English",

volume = "34",

pages = "154--9",

journal = "Leukemia research",

issn = "0145-2126",

publisher = "Elsevier Ltd.",

number = "2",

}

TY - JOUR

T1 - Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia

AU - Hartman, A

AU - van Schaik, R H N

AU - van der Heiden, I P

AU - Broekhuis, M J C

AU - Meier, M

AU - den Boer, M L

AU - Pieters, R

PY - 2010/2

Y1 - 2010/2

N2 - INTRODUCTION: Impaired motor performance in children who completed treatment for acute lymphoblastic leukemia (ALL) may be related to polymorphisms of the metabolising gene CYP3A5 or vincristine toxicity related genes MDR-1 and MAPT.METHODS: Motor performance was measured with the Movement Assessment Battery for Children (movement-ABC). DNA, from mononuclear blood cells was genotyped for CYP3A5, MDR-1 and MAPT polymorphisms.RESULTS: Motor performance was not significantly affected by CYP3A5*3/*3 and CYP3A5*1*3 genotypes, MDR-1 polymorphisms or MAPT haplotype.CONCLUSION: Our data did not show that CYP3A5, MDR-1 or MAPT polymorphisms are linked to impaired motor performance in children after treatment for ALL.

AB - INTRODUCTION: Impaired motor performance in children who completed treatment for acute lymphoblastic leukemia (ALL) may be related to polymorphisms of the metabolising gene CYP3A5 or vincristine toxicity related genes MDR-1 and MAPT.METHODS: Motor performance was measured with the Movement Assessment Battery for Children (movement-ABC). DNA, from mononuclear blood cells was genotyped for CYP3A5, MDR-1 and MAPT polymorphisms.RESULTS: Motor performance was not significantly affected by CYP3A5*3/*3 and CYP3A5*1*3 genotypes, MDR-1 polymorphisms or MAPT haplotype.CONCLUSION: Our data did not show that CYP3A5, MDR-1 or MAPT polymorphisms are linked to impaired motor performance in children after treatment for ALL.

KW - ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics

KW - Child

KW - Child, Preschool

KW - Cytochrome P-450 CYP3A/genetics

KW - Drug Resistance, Neoplasm/genetics

KW - Female

KW - Genotype

KW - Humans

KW - Male

KW - Pharmacogenetics

KW - Polymorphism, Genetic

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma/complications

KW - Psychomotor Performance/drug effects

KW - Vincristine/pharmacokinetics

KW - tau Proteins/genetics

U2 - 10.1016/j.leukres.2009.04.027

DO - 10.1016/j.leukres.2009.04.027

M3 - Article

C2 - 19467705

SN - 0145-2126

VL - 34

SP - 154

EP - 159

JO - Leukemia research

JF - Leukemia research

IS - 2

ER -

Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit